Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4514525 | 0.84 | GPR119 (0.74) | GPR119TGFBR1 | |
| SCHEMBL4507403 | 0.83 | GPR119 (0.58) | GPR119 | |
| SCHEMBL4504686 | 0.83 | GPR119 (0.69) | GPR119TGFBR1 | |
| SCHEMBL4507668 | 0.82 | GPR119 (0.54) | GPR119AKR1C3DRD2DRD3HTR1A | |
| SCHEMBL4512522 | 0.79 | GPR119 (0.70) | GPR119 | |
| SCHEMBL1576173 | 0.79 | GPR119 (0.53) | GPR119 | |
| SCHEMBL4524985 | 0.76 | GPR119 (0.61) | GPR119TGFBR1 | |
| SCHEMBL4503463 | 0.75 | GPR119 (0.61) | GPR119TGFBR1 | |
| SCHEMBL4513931 | 0.75 | GPR119 (0.61) | GPR119TGFBR1 | |
| SCHEMBL4513535 | 0.75 | GPR119 (0.72) | GPR119TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
| EP-1909791-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | Prosidion Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007003964-A1 | G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203676-A1 | G-protein Coupled Receptor Agonists | GPR119, GCGR, GPBAR1 | GPR119 1/4885AKR1C3 1609/4885DRD2 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.